Elegen’s patented ENFINIA™ DNA platform uses microfluidics, AI and robotics to deliver long, clonal quality, high complexity, DNA products with unprecedented speed, low costs, and efficiency.
Your sequence of interest as a linear construct.
1-7kb
Was $0.15/bp
Now $0.07/bp
Your sequence plus a poly(A) tail for in vitro transcription.
1-5.5kb
Was $0.15/bp (+ tailing fee)
Now $0.07/bp (+ tailing fee)
Your sequence cloned into a standard or custom plasmid backbone.
1-15kb
Was $0.16/bp
Now $0.12/bp
With ENFINIA Linear DNA, your sequence arrives NGS-verified and ready to use. No cloning. No colony screening. No extra sequencing runs.
Traditional gene fragments may arrive quickly, but they often require days of additional cloning, colony screening, and sequencing before they can be used. And clonal gene services can take 10+ business days before you even receive your construct.
ENFINIA Linear DNA removes those extra steps, giving you verified DNA you can trust on day one.
Skip cloning entirely
NGS-verified sequence accuracy
6–8 business day turnaround
Consistent pricing across longer constructs
Think ENFINIA DNA sounds expensive? Think again.
If you receive a quote for similar DNA at a lower price, we’ll match it. That means you can get high-accuracy, NGS-verified DNA—ready to use—at the same price as gene fragments that still require cloning.
Submit a quote for price matching and see how fast you can start your next experiment.
Rapid synthesis and production is essential for combating emerging infectious disease. Learn how mRNA templates enable fast response.
Learn how mRNA Templates enable the rapid and reliable production of patient-specific therapies.
Learn how ENFINIA linear DNA performs against traditional plasmids in cell-free protein expression kits and workflows.
FEATURED VIDEO
Produced from Elegen’s proprietary cell-free DNA production technology, ENFINIA DNA provides unprecedented speed, length, and quality. Shipped in 6 to 8 business days and up to 7 kb in length, ENFINIA DNA arrives NGS-verified with a 99.999% per base accuracy or 1:70,000 bp error rate, ready for immediate use without cloning.
FEATURED VIDEO
Introducing world’s first directed-split-pool microfluidic synthesizer with Elegen’s patented cell-free cloning technology, a unique combination of AI and robotics that fully automates the production of long, clonal quality, high complexity, double-stranded DNA with unprecedented speed, low costs, and efficiency.
Webinar
In this GEN webinar, our expert speakers will present a case study demonstrating the exceptional properties and high-fidelity performance of ENFINIA Linear DNA as evaluated in GeneFrontier’s cell-free protein synthesis PUREfrex® system. These results showcase ENFINIA’s outperformance in terms of DNA purity, transcription efficiency, and robust protein expression for various constructs. Originally aired Wednesday October 8th 2025 aT 8A PDT.
Webinar
Join the Elegen team as we explore a cell-free approach to generating high-complexity, linear IVT-ready DNA templates—built to accelerate and scale mRNA workflows. Hosted by DDN.
Don’t miss this deep dive into faster, more consistent mRNA production. Topics include:
• Key challenges in mRNA synthesis
• A robust, cell-free alternative to plasmid prep
• Performance data comparing IVT-ready linear DNA vs. plasmid-based methods
Jan 27, 2026
Elegen, today announced significant price reductions across its ENFINIA™ DNA portfolio, now offering high-accuracy, clonal, cell-free synthetic DNA with list pricing as low as $0.07 per base pair.
SOURCE: Businesswire
Announcing the early access launch of Elegen’s Gen II DNA Production Platform. This platform now incorporates the world’s first directed split-pool microfluidic synthesizer, which augments Elegen’s unique cell-free cloning technology that ends the reliance on plasmids.
Oct 28, 2025
SOURCE: Businesswire
Sep 09, 2025
Elegen’s cell-free gene synthesis platform delivers full-length, high-complexity linear DNA with encoded poly(A) tails up to three times faster and free from bioburden, endotoxins and recombination-mediated variation.
SOURCE: Businesswire
“The growing bioeconomy demands synthetic biology performs on a scale not possible without innovation of the DNA manufacturing process. Elegen will help the builders in the next evolution of synthetic biology eliminate expensive, time and capital-intensive workflows by using innovative methods and technologies to provide fast-turnaround, high-accuracy, complex, long, synthetic DNA.”
Matthew Hill
Founder and CEO of Elegen
